Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Monitoring the Activation of the DNA Damage Response Pathway in a 3D Spheroid Model.

Mondesert O, Frongia C, Clayton O, Boizeau ML, Lobjois V, Ducommun B.

PLoS One. 2015 Jul 30;10(7):e0134411. doi: 10.1371/journal.pone.0134411.

2.

CDC25B overexpression stabilises centrin 2 and promotes the formation of excess centriolar foci.

Boutros R, Mondesert O, Lorenzo C, Astuti P, McArthur G, Chircop M, Ducommun B, Gabrielli B.

PLoS One. 2013 Jul 1;8(7):e67822. doi: 10.1371/journal.pone.0067822.

3.

Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D.

Laurent J, Frongia C, Cazales M, Mondesert O, Ducommun B, Lobjois V.

BMC Cancer. 2013 Feb 8;13:73. doi: 10.1186/1471-2407-13-73.

4.

Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter.

Dalvai M, Mondesert O, Bugler B, Manenti S, Ducommun B, Dozier C.

Oncogene. 2013 Oct 17;32(42):5123-8. doi: 10.1038/onc.2012.524.

PMID:
23160377
5.

Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors.

Dalvai M, Mondesert O, Bourdon JC, Ducommun B, Dozier C.

Oncogene. 2011 May 12;30(19):2282-8. doi: 10.1038/onc.2010.588.

PMID:
21242964
6.

CDC25B associates with a centrin 2-containing complex and is involved in maintaining centrosome integrity.

Boutros R, Lorenzo C, Mondesert O, Jauneau A, Oakes V, Dozier C, Gabrielli B, Ducommun B.

Biol Cell. 2011 Feb;103(2):55-68. doi: 10.1042/BC20100111.

7.

5-Substituted [1]pyrindine derivatives with antiproliferative activity.

Kolb S, Goddard ML, Loukaci A, Mondésert O, Ducommun B, Braud E, Garbay C.

Eur J Med Chem. 2010 Mar;45(3):896-901. doi: 10.1016/j.ejmech.2009.11.028.

PMID:
19969400
8.

Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors.

Kolb S, Mondésert O, Goddard ML, Jullien D, Villoutreix BO, Ducommun B, Garbay C, Braud E.

ChemMedChem. 2009 Apr;4(4):633-48. doi: 10.1002/cmdc.200800415.

PMID:
19212959
9.

A caspase-dependent cleavage of CDC25A generates an active fragment activating cyclin-dependent kinase 2 during apoptosis.

Mazars A, Fernandez-Vidal A, Mondesert O, Lorenzo C, Prévost G, Ducommun B, Payrastre B, Racaud-Sultan C, Manenti S.

Cell Death Differ. 2009 Feb;16(2):208-18. doi: 10.1038/cdd.2008.142.

10.

Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties.

Braud E, Goddard ML, Kolb S, Brun MP, Mondésert O, Quaranta M, Gresh N, Ducommun B, Garbay C.

Bioorg Med Chem. 2008 Oct 1;16(19):9040-9. doi: 10.1016/j.bmc.2008.08.009.

PMID:
18789703
11.

Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors.

Montes M, Braud E, Miteva MA, Goddard ML, Mondésert O, Kolb S, Brun MP, Ducommun B, Garbay C, Villoutreix BO.

J Chem Inf Model. 2008 Jan;48(1):157-65.

PMID:
18154280
12.

CDC25B phosphorylation by p38 and MK-2.

Lemaire M, Froment C, Boutros R, Mondesert O, Nebreda AR, Monsarrat B, Ducommun B.

Cell Cycle. 2006 Aug;5(15):1649-53.

PMID:
16861915
13.

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases.

Brezak MC, Quaranta M, Contour-Galcera MO, Lavergne O, Mondesert O, Auvray P, Kasprzyk PG, Prevost GP, Ducommun B.

Mol Cancer Ther. 2005 Sep;4(9):1378-87.

14.

Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.

Brun MP, Braud E, Angotti D, Mondésert O, Quaranta M, Montes M, Miteva M, Gresh N, Ducommun B, Garbay C.

Bioorg Med Chem. 2005 Aug 15;13(16):4871-9.

PMID:
15921913
15.
16.

A novel synthetic inhibitor of CDC25 phosphatases: BN82002.

Brezak MC, Quaranta M, Mondésert O, Galcera MO, Lavergne O, Alby F, Cazales M, Baldin V, Thurieau C, Harnett J, Lanco C, Kasprzyk PG, Prevost GP, Ducommun B.

Cancer Res. 2004 May 1;64(9):3320-5.

17.

A fission yeast strain expressing human CDC25A phosphatase: a tool for selectivity studies of pharmacological inhibitors of CDC25.

Mondesert O, Lemaire M, Brezak MC, Galera-Contour MO, Prevost G, Ducommun B, Bugler B.

Curr Genet. 2004 May;45(5):283-8.

PMID:
14727060
18.

Inhibitors of the CDC25 phosphatases.

Prevost GP, Brezak MC, Goubin F, Mondesert O, Galcera MO, Quaranta M, Alby F, Lavergne O, Ducommun B.

Prog Cell Cycle Res. 2003;5:225-34. Review.

PMID:
14593717
19.

Human CDC25B and CDC25C differ by their ability to restore a functional checkpoint response after gene replacement in fission yeast.

Mondesert O, Ducommun B, Bugler B.

Biochem Biophys Res Commun. 2002 Jul 19;295(3):673-7.

PMID:
12099692
20.

Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein.

Lopez-Girona A, Furnari B, Mondesert O, Russell P.

Nature. 1999 Jan 14;397(6715):172-5.

PMID:
9923681
Items per page

Supplemental Content

Loading ...
Support Center